Skip to content
  • About
    • Supporter
    • Expert Index
    • Editorial Board
    • Editorial Team
    • Editorial Policy
  • Contact
  • Sign up

Visit

vjhemonc logo
VJRegenMed
Logo
  • Home (current)
  • Specialties
    Hematology
    Oncology
    Musculoskeletal Disorder
    Rare Disease
    Metabolic Disorder
    Cardiovascular Disease
    Ophthalmology
    Neurology
    Infectious Disease
    View all Specialties
  • Technologies
    Cell Therapy
    MSC
    iPSC
    Gene Therapy
    Genome Editing
    Extracellular Vesicles
    CAR-T Therapy
    TCR Therapy
    Tissue-Engineering & Biomaterials
    View all Technologies
  • Topics
    Treatment
    Immuno-Oncology
    Trial Updates
    Perspectives
    Manufacturing
    COVID-19
    View all Topics
  • Conferences
    ASH 2022
    TCT 2022
    Meeting on the Med 2022
    ICLE 2022
    Advanced Therapies Week 2022
    TERMIS 2021
    ESGCT 2021
    Meeting on the Mesa 2021
    Advanced Therapies 2021
    View all Conferences
    • About
      • Supporter
      • Expert Index
      • Editorial Board
      • Editorial Team
      • Editorial Policy
    • Contact
    • Sign up

safety

Results from a Phase I trial of rapidly manufactured Prgn-3006 Ultracar-T in R/R AML 2:08
Results from a Phase I trial of rapidly manufactured Prgn-3006 Ultracar-T in R/R AML
David Sallman • 11 Dec 2022
Phase I study of CC-98633 in R/R multiple myeloma 2:45
Phase I study of CC-98633 in R/R multiple myeloma
Luciano Costa • 11 Dec 2022
CAR T-cell therapy for neuroblastoma 2:24
CAR T-cell therapy for neuroblastoma
Shigeki Yagyu • 8 Apr 2022
Overexpression of the LBTR gene to optimize T cell proliferation 1:54
Overexpression of the LBTR gene to optimize T cell proliferation
Mateusz Legut • 31 Mar 2022
Challenges in manufacturing viral vectors for the clinic 4:51
Challenges in manufacturing viral vectors for the clinic
Nathalie Clement • 27 Jan 2022
Treating Krabbe disease with FBX-101 1:58
Treating Krabbe disease with FBX-101
John Maslowski • 27 Jan 2022
MOMENTUM: ARU-1801 in sickle cell disease 1:57
MOMENTUM: ARU-1801 in sickle cell disease
Will Chou • 26 Jan 2022
Clinical translation of biomaterials 3:09
Clinical translation of biomaterials
May Griffith • 12 Nov 2021
The safety of AVR-RD-01 gene therapy for Fabry disease 4:31
The safety of AVR-RD-01 gene therapy for Fabry disease
Mark Thomas • 29 Oct 2021
Applications of single-cell multi-omics analysis 7:04
Applications of single-cell multi-omics analysis
Yan Zhang • 21 Oct 2021
Utilizing single-cell multi-omics throughout the product pipeline 1:50
Utilizing single-cell multi-omics throughout the product pipeline
Yan Zhang • 21 Nov 2021
Liquid vs solid tumor strategies in cell therapy 2:17
Liquid vs solid tumor strategies in cell therapy
Kanya Rajangam • 13 Oct 2021
Advantages of allogeneic NK cell therapy 2:26
Advantages of allogeneic NK cell therapy
Kanya Rajangam • 13 Oct 2021
Developments in NK cell therapy 2:48
Developments in NK cell therapy
Kanya Rajangam • 13 Oct 2021
Treating hematologic malignancies with immunotherapy 0:59
Treating hematologic malignancies with immunotherapy
Kanya Rajangam • 13 Oct 2021
NKX019 in B-cell malignancies 1:05
NKX019 in B-cell malignancies
Kanya Rajangam • 13 Oct 2021
  • 1
  • 2
  • Next
Journal Pages
  • Specialties
  • Technologies
  • Topics
  • Conferences
Newsletter

Receive the latest news and videos from VJRegenMed via email

Sign up
Contact Us

Contact us for more information

mmp logo

Magdalen Centre
The Oxford Science Park
Oxford OX4 4GA, United Kingdom

VJRegenMed logo
The content of VJRegenMed is intended for healthcare professionals
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
  • Editorial Policy